Opendata, web and dolomites

MECADISTEM

A new and innovative method to extract adipose Stromal Vascular Fraction: Application in post-prostatectomy erectile dysfunction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MECADISTEM project word cloud

Explore the words cloud of the MECADISTEM project. It provides you a very rough idea of what is the project "MECADISTEM" about.

cancer    urologists    damages    market    collagenase    cellular    proven    avoiding    medical    imposed    savings    men    time    post    frequent    tools    finalise    prostatectomy    tissue    efficient    unmet    clinical    damaged    rp    surgeons    filtration    cells    grinding    patients    progenitor    alternatives    repair    surgical    operations    cure    mecadistem    minutes    stemcis    once    complication    enzymes    hire    extract    form    view    substantial    million    adult    ed    simply    methodology    gain    kit    regenerating    treatment    radical    erectile    svf    dysfunction    treat    roi    enzymatic    centrifugation    tissues    extracted    hold    feasibility    quality    isolate    mechanically    therapies    shown    validated    point    cell    single    milestones    stem    candidate    preclinical    fraction    financial    vascular    people    impairs    28    profits    expecting    prostate    constraints    secure    digestion    adipose    preparation    life    stromal    money    12    commercial   

Project "MECADISTEM" data sheet

The following table provides information about the project.

Coordinator
STEMCIS SAS 

Organization address
address: 2 RUE MAXIME RIVIERE
city: SAINTE CLOTILDE
postcode: 97490
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.stemcis.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STEMCIS SAS FR (SAINTE CLOTILDE) coordinator 50˙000.00

Map

 Project objective

Erectile dysfunction (ED) is a significant and common medical problem which impairs quality of life of men and their partners. ED is a frequent complication after a radical prostatectomy (RP) due to surgical treatment for prostate cancer. For this condition, ED represents a significant unmet medical need, since there is no efficient treatment to repair the cellular damages following a RP. Clinical implementation of stem cell treatment represents a potential candidate for ED treatment after RP. Adult progenitor cells extracted from adipose tissue, called Stromal Vascular Fraction (SVF) have shown promising results in preclinical and clinical studies to treat post-RP ED. STEMCIS has developed a unique kit to isolate the adipose cells which hold the potential to cure post-prostatectomy ED by regenerating the damaged tissues. MECADISTEM comes in the form of a single-use kit that includes all the tools necessary to simply and rapidly (less than 30 minutes) extract adipose tissue progenitor cells mechanically (grinding, centrifugation, filtration). Compared to the state-of-the-art alternatives using “collagenase (enzymatic) digestion”, MECADISTEM does not require the use of enzymes, avoiding the problems and constraints imposed by the use of this enzymatic digestion and offering substantial time and money savings, on both technical and surgical operations. Having validated this methodology in preclinical study, this project is planned to finalise the development and market preparation of this kit. In this Phase 1 Feasibility Study, we aim to evaluate the main milestones of the project from a technical, commercial and financial point of view. Once in the market, MECADISTEM will be used by urologists and surgeons to cure ED in patients following a RP, where the current therapies have not been proven effective. It will secure the growth for STEMCIS, expecting to gain over €12 million in profits, hire 6 new people and reach a ROI of €6.28 from this project after 5 years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MECADISTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MECADISTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

RoboSynFarm (2019)

Robotic Synthesis Farm

Read More